APA (7th ed.) Citation
(2026). RIPK2 induces docetaxel resistance in prostate cancer through the NF-κB/P-gp signaling pathway. PLOS ONE.
Chicago Style (17th ed.) Citation
"RIPK2 Induces Docetaxel Resistance in Prostate Cancer Through the NF-κB/P-gp Signaling Pathway." PLOS ONE 2026.
MLA (9th ed.) Citation
"RIPK2 Induces Docetaxel Resistance in Prostate Cancer Through the NF-κB/P-gp Signaling Pathway." PLOS ONE, 2026.
Warning: These citations may not always be 100% accurate.